Associate Editor

Robert T. Naismith, MD, serves as Neurology Clerkship Director at Washington University in St. Louis and has interests in medical education and teaching evidence-based manuscript review. He specializes in inflammatory diseases of the central nervous system, such as multiple sclerosis and neuromyelitis optica. His clinical investigations use quantitative magnetic resonance imaging sequences to better correlate imaging with clinical disease and to predict long-term outcome. He is also interested in clinical trials and clinical outcomes measures.
Alexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
National Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Consortium of Multiple Sclerosis Centers (Treasurer)